PBCD34+ is a human progenitor cell platform comprising haematopoietic stem cells sourced from mobilised human peripheral blood. CD34+ is a phosphoglycoprotein cell-surface marker that is known to characterise haematopoietic stem or progenitor cells residing in the bone marrow (and cord blood), and in maintaining them in an undifferentiated state. These stem cells are multipotent and have the potential to differentiate into all the various human lymphohaematopoietic lineages. Injection of G-CSF or Moxobil (into donor) causes the proliferation of these cells in the bone marrow and their subsequent migration into the peripheral circulation, or mobilisation, from where they are collected by leukepheresis. The CD34+ cells are isolated from the leukepheresis cell collection by immunomagnetic positive selection.
CBCD34+ cells are provided in customised cell numbers per vial, are ready-to-use and require no culturing process. Care is taken to ensure the safety of the donor and the integrity of collected cells, and all cell collection and handling procedures are compliant with government and Institutional Ethics Committee (IEC). Donors are tested for infection by HIV-1, HIV-2, HBV, HCV, Mycoplasma, Bacteria, Yeast and Fungi before collection. Cells are processed and checked for bioburden.
PBCD34+ cells can be induced to differentiate into the different lymphoid and myeloid lineages using established lab based protocols. The product is recommended for developing humanised mouse models for various infectious and non-infectious diseases. It is also intended for other pre-clinical applications such as in in-vitro HTS, for drug candidate efficacy and haematotoxicity, in oncology and regenerative medicine. They are also intended for exploratory preclinical studies in cancer immunotherapy, immunoregulation, transplant immunology, and HIV research, among others.
Disclaimer: Product for in vitro research use only. Not approved for diagnostic, therapeutic, or clinical applications. Not approved for human use in vivo.